Connor, Clark & Lunn Investment Management Ltd. Moon Lake Immunotherapeutics Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$38.43 - $48.6 $680,864 - $861,046	-17,717 Reduced 70.51%	7,409 $325,000
Q1 2024 May 09, 2024	BUY	$43.78 - $63.86 $345,424 - $503,855	7,890 Added 45.78%	25,126 $1.26 Million
Q4 2023 Feb 09, 2024	BUY	$36.35 - $63.02 $626,528 - $1.09 Million	17,236 New	17,236 $1.04 Million
Q2 2023 Aug 10, 2023	BUY	$19.01 - $51.79 $179,093 - $487,913	9,421 New	9,421 $480,000

Others Institutions Holding MLTX

# of Institutions

124

Shares Held

58.2M

Call Options Held

52.2K

Put Options Held

38K

Bvf Inc San Francisco, CA

21.8M
Shares

$1.13 Billion
34.86% of portfolio
Cormorant Asset Management, LP Boston, MA

8.49M
Shares

$442 Million
30.01% of portfolio
Price T Rowe Associates Inc Baltimore, MD

2.98M
Shares

$155 Million
0.02% of portfolio
Avoro Capital Advisors LLC New York, NY

2.77M
Shares

$144 Million
2.1% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.32M
Shares

$121 Million
0.02% of portfolio

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.92B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account